This novel anti-infective, invented by Orchid Pharma, aims to address the rising threat of antimicrobial resistance (AMR) and has been approved for the treatment of complicated urinary tract infections (cUTI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP)
Read More
The facility has been granted a Voluntary Action Indicated (VAI) status following an inspection that took place from May 7 to May 17, 2024
Read More
